These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 10639382

  • 1. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Brueggemann AB, Doern GV, Huynh HK, Wingert EM, Rhomberg PR.
    Antimicrob Agents Chemother; 2000 Feb; 44(2):447-9. PubMed ID: 10639382
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis.
    Schmitz FJ, Schwarz S, Milatovic D, Verhoef J, Fluit AC.
    J Antimicrob Chemother; 2002 Jul; 50(1):145-8. PubMed ID: 12096026
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of the ketolide ABT-773.
    Barry AL, Fuchs PC, Brown SD.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2922-4. PubMed ID: 11557491
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.
    Wootton M, Bowker KE, Janowska A, Holt HA, MacGowan AP.
    J Antimicrob Chemother; 1999 Oct; 44(4):445-53. PubMed ID: 10588304
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
    Critchley IA, Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Murfitt K, Sahm DF.
    Antimicrob Agents Chemother; 2002 Feb; 46(2):550-5. PubMed ID: 11796376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
    Barry AL, Fuchs PC, Brown SD.
    Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.
    Ling TK, Lee CC.
    Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628
    [Abstract] [Full Text] [Related]

  • 20. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
    Drago L, De Vecchi E, Nicola L, Colombo A, Gismondo MR.
    J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.